Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Myncov1006
- Development stage
- Preclinical
- Lead developer
- Mynvax
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
Myncov1006 is an engineered, recombinant protein subunit vaccine candidate developed by Mynvax for the prevention of COVID-19. The vaccine is designed to target the Receptor Binding Domain (RBD) and other highly conserved regions of the SARS-CoV-2 Spike protein to elicit a broad and potent immune response. A key feature of Mynvax's technology is the development of thermostable 'warm vaccines' that can withstand higher temperatures, potentially simplifying distribution by reducing reliance on cold-chain infrastructure. Myncov1006 is intended to provide protection against multiple variants of the virus by focusing on epitopes that are less prone to mutation. It is currently in the preclinical stage of development.
02
Targets
SARS-CoV-2 spike
Beyond the preview
Go deeper on Myncov1006.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Myncov1006.